Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zevalin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fludarabine, Mitoxantrone, Rituximab, Zevalin | EXPERIMENTAL | Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression. |
| Name | Type | Description |
|---|---|---|
| Fludarabine | DRUG | Given on days 1-3 of each 28-day cycle |
| Mitoxantrone | DRUG | Given on day 1 of each 28-day cycle |
| Rituximab | DRUG | Given on day 1 of each 28-day cycle |
| Zevalin | DRUG | After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose. |
Inclusion Criteria: * Histologically confirmed mantle cell lymphoma in 1st or 2nd relapse, or with persistent disease following induction therapy. * Measurable disease (lymph node \> 1.5 cm) * No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study...
Zevalin is used for the treatment of Mantle Cell Lymphoma, a type of non-Hodgkin lymphoma. It is being studied as part of a chemotherapy regimen followed by Zevalin for patients with relapsed disease. The drug is currently in clinical development for this indication.
Zevalin is developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Mantle Cell Lymphoma.
Zevalin is in Phase 2 clinical development for Mantle Cell Lymphoma. A Phase 2 trial has been completed, which enrolled 30 participants in the United States. The drug is investigational and has not yet been approved for this use.
Zevalin has one completed clinical trial, identified as NCT00119730, titled "Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma." This Phase 2 study enrolled 30 patients in the United States and was not randomized or blinded.
Yes, Zevalin is classified as a small molecule drug. It is being developed as an oncology treatment for Mantle Cell Lymphoma, and its clinical trial included biomarker-selected patients, indicating a targeted approach to patient selection.